Current partner codePEPTIDESDE
NCT01788462·Not applicable·OBSERVATIONAL

Egrifta Replacement and Sleep Disordered Breathing

Status

Withdrawn

Phase

Not applicable

Enrollment

0

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Sleep-disordered breathing is characterized primarily by partial or total upper airway obstruction during sleep. The most common form of sleep-disordered breathing is obstructive sleep apnea (OSA) due to recurrent collapse of the upper airway with the onset of sleep state. The major risk factors associated with the development of sleep apnea are obesity and male sex. The investigators have also found a high prevalence of OSA in HIV infected men and women, particularly among those with central lipohypertrophy, which is a common finding in HIV-infected persons receiving antiretroviral therapy. Currently, our overall hypothesis is that visceral adiposity, as seen in HIV-infected persons with central lipohypertrophy, alters both mechanical properties and compensatory neuromuscular responses leading to upper airway obstruction. Based on our most recent findings in the non-HIV population, the investigators demonstrate that obesity is associated with elevations in the upper airway load (passive Pcrit) that are counterbalanced by compensatory upper airway neural responses. Moreover, the investigators have found that female sex, peripheral adiposity, and younger age are associated with increased compensatory neuromuscular responses, while male sex, central adiposity, and older age are associated with blunted compensatory responses. The loss of the compensatory neuromuscular responses leads to obstructive sleep apnea. Among HIV-infected patients with central lipohypertrophy, tesamorelin (Egrifta), a growth hormone releasing hormone (GHRH) analogue, is approved for the reduction of visceral adipose tissue. The investigators hypothesize that tesamorelin therapy will reverse both the mechanical and neurocompensatory alterations associated with increased central obesity. In this project the investigators will determine whether tesamorelin affects sleep apnea severity and compensatory neuromuscular responses of the upper airway on sleep and breathing in men and women with HIV infection. The proposed studies are designed to elucidate the pathophysiologic basis for the development of obstructive sleep apnea in this population. The studies also provide insights into the neurohumoral regulation of upper airway function, and potentially new approaches to the treatment for sleep-disordered breathing.

Interventions

Treatment arms and agents.

DRUG

Tesamorelin (Egrifta)

We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.

Timeline

From registration to results.

  1. First posted

    Feb 11, 2013

  2. Study start

    May 2012

  3. Primary completion

    Jan 2020

  4. Study completion

    Not reported

  5. Results posted

    Not reported

  6. Registry updated

    Mar 3, 2017

Outcomes

What the study measures.

Primary outcomes

Changes in Sleep Apnea Severity

Time frame · Subjects will be evaluated prior to initiating tesamorelin therapy (baseline)

Sleep apnea severity (AHI), change in sleep apnea severity (∆ AHI), and compensatory neuromuscular responses (AT/DBT, ∆ AT/DBT) will be the primary outcome variables.

Changes in Sleep Apnea Severity

Time frame · Subjects will be evaluated at three months

Sleep apnea severity (AHI), change in sleep apnea severity (∆ AHI), and compensatory neuromuscular responses (AT/DBT, ∆ AT/DBT) will be the primary outcome variables.

Changes in Sleep Apnea Severity

Time frame · Subjects will be evaluated at six months

Sleep apnea severity (AHI), change in sleep apnea severity (∆ AHI), and compensatory neuromuscular responses (AT/DBT, ∆ AT/DBT) will be the primary outcome variables.

Changes in Sleep Apnea Severity

Time frame · Subjects will be evaluated at one year

Sleep apnea severity (AHI), change in sleep apnea severity (∆ AHI), and compensatory neuromuscular responses (AT/DBT, ∆ AT/DBT) will be the primary outcome variables.

Secondary outcomes

Changes in Body Composition

Time frame · baseline

Secondary outcomes will include the percent change in anthropometric and body composition parameters as reflected by Dual-Energy Xray Absorbtiometry measurements.

Changes in Body Composition

Time frame · 12 months

Secondary outcomes will include the percent change in anthropometric and body composition parameters as reflected by Dual-Energy Xray Absorbtiometry measurements.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
75 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: 1. Consenting adult with documented HIV-infection, ages 18 - 75 years old 2. Central lipohypertrophy as determined by a clinician 3. Not currently on Egrifta (tesamorelin) therapy. Exclusion Criteria: 1. Unstable cardiovascular disease (decompensated CHF, myocardial infarction in past 3 months, revascularization procedure in past 3 months, and unstable arrhythmias); 2. Uncontrolled hypertension (BP \> 190/110); 3. Presence of cor pulmonale 4. History of end stage renal disease (on dialysis); 5. History of end stage liver disease ( e.g. jaundice, ascites, history of recurrent gastrointestinal bleeding, transjugular intrahepatic portosystemic shunt (TIPS) ; 6. Bleeding disorders or coumadin use; 7. Tracheostomy 8. Active malignancy 9. Pregnancy and/or nursing mother -

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Johns Hopkins Sleep Disorders Center

Baltimore, Maryland, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Tesamorelin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.